PURPOSE. This study evaluated the effect of transforming growth factor (TGF)-�2 and anti–TGF-�2 antibody in a rodent model of posterior capsule opacification (PCO). METHODS. An extracapsular lens extraction (ECLE) was performed in 72 Sprague–Dawley rats. At the end of the procedure, 10 �L TGF-�2 (TGF-�2–treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control group), a human monoclonal TGF-�2 antibody (anti–TGF-�2– treated group), or a null control IgG4 antibody (null antibody– treated control group) was injected into the capsule. Animals were killed 3 and 14 days postoperatively. Eyes were evaluated clinically prior to euthanatization, then enucleated and processed for light microscopy and immunohistochemistry afterward. PCO was evaluated clinically and histopathologically. Student’s t-test and � 2 were used to assess differences between groups. RESULTS. There were no statistically significant clinical or histopathological differences in degree of PCO between the TGF-�2 – and FCS/PBS-treated groups at 3 and 14 days after ECLE. Nor were there differences between the anti–TGF-�2 – and the null antibody–treated groups, with the exception of the histopathology score for capsule wrinkling 3 days after ECLE (P � 0.02). �-Smooth-muscle actin staining was observed in the lens capsular bag only in areas where there was close contact with the iris. CONCLUSIONS. No sustained effect of TGF-�2 or anti–TGF-�2 antibody on PCO was found in rodents at the dose and timing administered in this study. Iris cells may play a role in the process of epithelial mesenchymal transition linked to PCO
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.